Fulcrum Therapeutics, Inc. (FULC)
NASDAQ: FULC · Real-Time Price · USD
3.800
+0.190 (5.26%)
At close: Jun 26, 2026, 4:00 PM EDT
3.730
-0.070 (-1.84%)
After-hours: Jun 26, 2026, 6:57 PM EDT
Fulcrum Therapeutics Employees
Fulcrum Therapeutics had 55 employees as of December 31, 2025. The number of employees increased by 10 or 22.22% compared to the previous year.
Employees
55
Change (1Y)
10
Growth (1Y)
22.22%
Revenue / Employee
n/a
Profits / Employee
-$1,383,927
Market Cap
253.21M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Fate Therapeutics | 161 |
| Coherus Oncology | 145 |
| AC Immune | 122 |
| Foghorn Therapeutics | 106 |
| Orchestra BioMed Holdings | 86 |
| Cybin | 50 |
| ALX Oncology Holdings | 43 |
| Anavex Life Sciences | 34 |
FULC News
- 24 days ago - Fulcrum Therapeutics downgraded to Underweight from Overweight at JPMorgan - TheFly
- 24 days ago - Goldman suspends rating on Fulcrum Therapeutics - TheFly
- 24 days ago - Fulcrum Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information about Potentially Recovering Their Losses - GlobeNewsWire
- 24 days ago - Fulcrum Therapeutics price target lowered to $3 from $8 at BofA - TheFly
- 24 days ago - Fulcrum plummets 50% after scrapping lead sickle-cell drug on FDA concerns - Reuters
- 24 days ago - Fulcrum Therapeutics downgraded to Market Perform from Outperform at Leerink - TheFly
- 24 days ago - Fulcrum Therapeutics downgraded to Neutral from Buy at H.C. Wainwright - TheFly
- 24 days ago - Fulcrum Therapeutics downgraded to Market Perform from Outperform at Leerink - TheFly